IMU Biosciences Brings Series A to Over $53M for Immune Decoding

Fundraise Insider tracks newly funded startups each week and delivers verified C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

IMU Biosciences, a biotech company based in London, England in the United Kingdom, has closed an oversubscribed financing round that brings its Series A to over $53 million. The round was announced on June 1, 2026.

IQ Capital and Molten Ventures co-led the financing, with support from The British Business Bank and Meltwind alongside existing investors.

The company was founded by a team of experimental immunologists and computational biologists who bring more than a decade of expertise from the Francis Crick Institute and King’s College London. By combining high-fidelity multi-omic analysis with proprietary machine learning analytics, IMU can use a simple blood sample to measure over 100 million immune data points, creating what it describes as the most detailed immune picture ever assembled at clinical scale. The company says it has built the world’s largest immune dataset, scaling to more than 25,000 individuals in 2026 through broad access to patient samples and population-wide clinical data.

The proceeds will support operational expansion and the development of IMU’s clinical platform and infrastructure. The capital will also advance the company’s clinical programs, including its Stem Cell Transplant and Solid Organ Transplant programs, along with MANIFEST, a UK research consortium investigating patient response to cancer immunotherapies.